DM
Therapeutic Areas
Affimed Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AFM13 (acimtamig) | Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) | Phase 2 |
| AFM24 | Advanced EGFR-expressing Solid Tumors (e.g., NSCLC, Colorectal Cancer) | Phase 1/2a |
| AFM28 | CD123-positive Hematological Malignancies (e.g., Acute Myeloid Leukemia) | Phase 1 |
Leadership Team at Affimed
DA
Dr. Andreas Harstrick
Chief Medical Officer (Acting Chief Executive Officer)
DW
Dr. Wolfgang Fischer
Chief Operating Officer
DA
Dr. Andreas Rutten
Chief Development Officer
DA
Dr. Anthony (Tony) Ho
Chief Scientific Officer
DM
Dr. Martin Treder
Chief Scientific Officer, Research & Technology Innovation
DN
Dr. Natalia Martin
Chief Business Officer
DA
Dr. Adi Hoess
Strategic Advisor (Former Chief Executive Officer)
DA
Dr. Arndt Schottelius
Founder & Chief Scientific Officer (Founding Role)
DM
Dr. Michael Wolf
Member of the Supervisory Board
DC
Dr. Christine Roth
Member of the Supervisory Board